Biotron Limited
BITRF
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.29M
Close$
$-0.00
186.7% downside
Current Fair Value
186.7% downsideOvervalued by 186.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.29 Million |
|---|---|
| Enterprise Value | $1.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | -0.64 |
| Outstanding Shares | 2,701,871,644 |
Return
| Return on Equity | -62.93% |
|---|---|
| Return on Assets | -49.17% |
| Return on Invested Capital | -77.64% |
Valuation & Multiples
| P/E Ratio | -3.56 |
|---|---|
| PEG | 8.63 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.74 |
| Enterprise Value to EBIT | -0.77 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biotron Limited
4 employees
CEO: Michelle Miller GCertAppFin Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently underg...